Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIBF1 regulates trophoblast syncytialization and promotes cardiovascular development.
Lee JG, Yon JM, Kim G, Lee SG, Kim CY, Cheong SA, Kim HY, Yu J, Kim K, Sung YH, Yoo HJ, Woo DC, Rho JK, Ha CH, Pack CG, Oh SH, Lim JS, Han YM, Hong EJ, Seong JK, Lee HW, Lee SW, Lee KU, Kim CJ, Nam SY, Cho YS, Baek IJ. Lee JG, et al. Among authors: woo dc. Nat Commun. 2024 Feb 19;15(1):1487. doi: 10.1038/s41467-024-45647-8. Nat Commun. 2024. PMID: 38374152 Free PMC article.
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.
Rho JK, Lee IY, Choi YJ, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, Baek IJ, Lee JY, Ha CH, Sung YH, Kim JK, Kim WS, Song JS, Kim CH, Bivona TG, Lee JC. Rho JK, et al. Among authors: woo dc. Cancer Res. 2017 Mar 1;77(5):1200-1211. doi: 10.1158/0008-5472.CAN-16-2432. Epub 2017 Jan 12. Cancer Res. 2017. PMID: 28082405 Free PMC article.
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: woo dc. Cancer Res. 2022 Jun 14:canres.0394.2022-2-3 21:03:12.200. doi: 10.1158/0008-5472.CAN-22-0394. Online ahead of print. Cancer Res. 2022. PMID: 35700239 Retracted.
Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: woo dc. Cancer Res. 2022 Aug 25:OF1. doi: 10.1158/0008-5472.CAN-22-2377. Online ahead of print. Cancer Res. 2022. PMID: 36006687 No abstract available.
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: woo dc. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Online ahead of print. Cancer Res. 2022. PMID: 36018295 No abstract available.
Dynamic contrast-enhanced MRI for oncology drug development.
Sung YS, Park B, Choi Y, Lim HS, Woo DC, Kim KW, Kim JK. Sung YS, et al. Among authors: woo dc. J Magn Reson Imaging. 2016 Aug;44(2):251-64. doi: 10.1002/jmri.25173. Epub 2016 Feb 8. J Magn Reson Imaging. 2016. PMID: 26854494 Review.
92 results